A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease
← catalyst calendarNCT07677358 · readout in 359 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Other
Enrollment
28estimated
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-09 | estimated | When the study began enrolling |
| Primary completion | 2027-08-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-09-10 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Hepatic Impairment
- Healthy, Hepatic Insufficiency
- Healthy Adults
Intervention
- Drug: Atirmociclib — also filed as PF-07220060
Primary outcomes
what the primary-completion date above is the date OFMaximum Observed Plasma Concentration (Cmax) for atirmociclib in participants with normal hepatic function
measured Pre-dose and at, 1, 2, 4, 6, 8, 12, and 24, 36, 48, 60, 72, 96, 120, 144 hours after a single oral dose
Maximum Observed Plasma Concentration (Cmax) for atirmociclib in participants with hepatic impairment
measured Pre-dose and at, 1, 2, 4, 6, 8, 12, and 24, 36, 48, 60, 72, 96, 120, 144, 168, 192 hours after a single oral dose
Area under the curve from time zero to extrapolated infinite time [AUC (0 - ∞)] for atirmociclib in participants with normal hepatic function
measured Pre-dose and at, 1, 2, 4, 6, 8, 12, and 24, 36, 48, 60, 72, 96, 120, 144 hours after a single oral dose
Area under the curve from time zero to extrapolated infinite time [AUC (0 - ∞)] for atirmociclib in participants with impaired hepatic function
measured Pre-dose and at, 1, 2, 4, 6, 8, 12, and 24, 36, 48, 60, 72, 96, 120, 144, 168, 192 hours after a single oral dose
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed